Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib

• Status: Terminated
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

IPI-504-06 is a Phase 3, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of IPI-504 as compared to placebo in patients with metastatic and/or unresectable GIST following failure of at least imatinib and sunitinib.

Approximately 195 patients will be randomized using a 2:1 ratio to receive either IPI-504 (N=130) or placebo (N=65). Upon unblinding, patients receiving either IPI-504 or placebo may receive IPI-504 in the open-label portion of the study if defined inclusion criteria are met.

Early and frequent imaging timepoints (Weeks 2, 5, 8, 14 and every 6 weeks thereafter) are incorporated into this study to capture progression events and limit patient exposure to ineffective agents.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Infinity Pharmaceuticals, Inc.
• Collaborators: AstraZeneca; MedImmune LLC
• Treatments: Imatinib Mesylate; Sunitinib

Criteria

Inclusion Criteria:

• At least 18 years of age at the time of study randomization.

• Histologically confirmed metastatic and/or unresectable GIST.

• Measurable disease on CT or MRI as defined by RECIST.

• Documented radiographic progression or intolerance to imatinib and sunitinib.

• Clinical failure of the most recent prior therapy for GIST. Note: There is no limit to the number of prior therapies a patient may have received.

• Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1.

• Hemoglobin ≥ 8.0 g/dL (80 g/L).

• Absolute Neutrophil Count ≥ 1500/µL (1.5 x 109/L).

• Platelets ≥ 100,000 /µL (100 x 109/L).

• ALT and AST ≤ 2.5 x upper limit of normal (ULN), or ≤ 5.0 x ULN if considered secondary to liver metastases.

• Alkaline phosphatase ≤ 2.5 x ULN, or ≤ 5.0 x ULN if considered secondary to liver metastases.

• Serum bilirubin ≤ 1.5 x ULN.

• PT and PTT ≤ 1.5 x ULN unless the patient is receiving warfarin. If the patient is receiving warfarin, the INR must be within therapeutic range.

• Serum creatinine ≤ 1.5 x ULN.

Exclusion Criteria:

• Previous administration of other known heat shock protein 90 (Hsp90) inhibitors.

• Surgery, radiotherapy, or lesion ablative procedure to the only area of measurable disease.

• Initiation or discontinuation of concurrent medication that is a potent CYP3A inhibitor less than 2 weeks prior to administration of IPI-504 or placebo.

• History of any of the following within the last 6 months: cardiac disease such as acute coronary syndrome or unstable angina, symptomatic congestive heart failure, uncontrolled hypertension, cirrhotic liver disease, cerebrovascular accident, or any other significant co-morbid condition or disease which, in the judgment of the investigator, would place the patient at undue risk or interfere with the study.

• Grade 3 or 4 hemorrhagic event within the last 6 months.

• Known human immunodeficiency virus positivity.

• Sinus bradycardia (resting heart rate < 50 bpm) secondary to intrinsic conduction system disease.

• QTcF ≥ 470 milliseconds, or previous history of clinically significant QTc prolongation while taking other medications.

• History of prior malignancies within the past 3 years other than non-melanomatous skin cancers that have been controlled, prostate cancer that has been treated and has not recurred, non-muscle-invasive bladder cancer, and carcinoma in situ of the cervix.

• Active or recent history (within 3 months) of keratitis or keratoconjunctivitis confirmed by ophthalmology or optometry exam.

• Presence of Left Bundle Branch Block, Right Bundle Branch Block plus left anterior hemiblock, bifascicular block, or 3rd degree heart block. This does not include patients with a history of these events with adequate control by pacemaker.

• Known CNS metastases.

• Women who are pregnant or lactating.